PanOptica

PanOptica strives to overcome the constraints of current treatments for severe ophthalmic conditions by creating a topical eye drop substitute for intravitreal (back-of-the eye) injection therapies. PanOptica, Inc., is a private, clinical-stage biopharmaceutical company dedicated to developing a topical eye drop for treating vision-endangering eye ailments resulting from abnormal or leaking blood vessels. These neovascular eye conditions encompass neovascular age-related macular degeneration (wet AMD), the primary cause of vision loss in the Western world, and diabetic retinopathy.